MDT-AP-0535
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 11.76
- os_event
- true
- age_years
- 5.18
- sex
- M
- new_clusters
- C2
- umap1_2d
- 1.873739943
- umap2_2d
- 0.035393583
- umap1_3d
- -0.809340034
- umap2_3d
- -2.079284699
- umap3_3d
- -0.686350516
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.700
- E2F_TARGETS+0.590
- MYC_TARGETS_V1+0.590
- G2M_CHECKPOINT+0.540
- NOTCH_SIGNALING+0.380
- MTORC1_SIGNALING+0.350
- ANGIOGENESIS+0.340
- MYOGENESIS+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.340
- DNA_REPAIR+0.300
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.410
- INTERFERON_GAMMA_RESPONSE-0.300
- PROTEIN_SECRETION-0.240
- INTERFERON_ALPHA_RESPONSE-0.230
- KRAS_SIGNALING_UP-0.220
- PANCREAS_BETA_CELLS-0.180
- SPERMATOGENESIS-0.140
- COAGULATION-0.100
- BILE_ACID_METABOLISM-0.090
- COMPLEMENT-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598165 | fetal | fetal | 0.825 |
| 2 | TCGA-56-A5DR-01A-11R-A27Q-07 | — | cohortSQ1 | 0.825 |
| 3 | MNG1082 | — | — | 0.788 |
| 4 | ERR2598170 | fetal | fetal | 0.787 |
| 5 | TCGA-85-7843-01A-11R-2125-07 | — | cohortSQ1 | 0.781 |
| 6 | MDT-AP-0375 | Med | Medulloblastoma | 0.781 |
| 7 | b038a717-19be-40c4-a4df-992156b5e2a2 | — | — | 0.775 |
| 8 | FB7673F7-FF7F-4C3C-A8C6-9C11C6BB71D5 | — | — | 0.774 |
| 9 | MDT-AP-0181 | Med | Medulloblastoma | 0.770 |
| 10 | MDT-AP-0322 | Med | Medulloblastoma | 0.770 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.700 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.540 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.340 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.270 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.080 | Idelalisib | — uncovered |